Risk factors for migraine disease progression: a narrative review for a patient-centered approach.

Autor: Lipton RB; Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA., Buse DC; Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.; Vector Psychometric Group, LLC, Chapel Hill, NC, USA., Nahas SJ; Department of Neurology, Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA., Tietjen GE; University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA., Martin VT; University of Cincinnati Headache and Facial Pain Center, Cincinnati, OH, USA., Löf E; H. Lundbeck A/S, Copenhagen, Denmark., Brevig T; H. Lundbeck A/S, Copenhagen, Denmark., Cady R; Lundbeck LLC, Deerfield, IL, USA.; RK Consults, Ozark, MO, USA.; Missouri State University, Springfield, MO, USA., Diener HC; Institute for Medical Informatics, Biometry and Epidemiology, Medical Faculty, University Duisburg-Essen, Essen, Germany. hans.diener@uk-essen.de.
Jazyk: angličtina
Zdroj: Journal of neurology [J Neurol] 2023 Dec; Vol. 270 (12), pp. 5692-5710. Date of Electronic Publication: 2023 Aug 24.
DOI: 10.1007/s00415-023-11880-2
Abstrakt: Background: In individuals with migraine, attacks may increase in frequency, severity, or both. Preventing migraine progression has emerged as a treatment goal in headache subspecialty practice, but there may be less awareness in general neurology or primary care settings where most people with migraine who seek treatment consult. Herein, we review the definition of and risk factors for migraine progression and consider strategies that could reduce its risk.
Methods: A group of headache expert healthcare professionals, clinicians, and researchers reviewed published evidence documenting factors associated with increased or decreased rates of migraine progression and established expert opinions for disease management recommendations. Strength of evidence was rated as good, moderate, or based solely on expert opinion, using modified criteria for causation developed by AB Hill.
Results: Migraine progression is commonly operationally defined as the transition from ≤ 15 to ≥ 15 monthly headache days among people with migraine; however, this does not necessarily constitute a fundamental change in migraine biology and other definitions should be considered. Established and theoretical key risk factors for migraine progression were categorized into five domains: migraine disease characteristics, treatment-related factors, comorbidities, lifestyle/exogenous factors, and demographic factors. Within these domains, good evidence supports the following risk factors: poorly optimized acute headache treatment, cutaneous allodynia, acute medication overuse, selected psychiatric symptoms, extra-cephalic chronic pain conditions, metabolism-related comorbidities, sleep disturbances, respiratory conditions, former/current high caffeine intake, physical inactivity, financial constraints, tobacco use, and personal triggers as risk factors. Protective actions that may mitigate migraine progression are sparsely investigated in published literature; our discussion of these factors is primarily based on expert opinion.
Conclusions: Recognizing risk factors for migraine progression will allow healthcare providers to suggest protective actions against migraine progression (Supplementary Fig. 1). Intervention studies are needed to weight the risk factors and test the clinical benefit of hypothesized mitigation strategies that emerge from epidemiological evidence.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: